Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19
| Autor: | Jay Pang, Damien Mack, Michael Spiro, Clare Bristow, Emmanuel Wey, Indran Balakrishnan, Gabriele Pollara, Shuang Yang, Aarti Nandani, Sanjay Bhagani, Bryan O'Farrell, Marisa Lanzman, Soo Ho |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
musculoskeletal diseases
Microbiology (medical) 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Interleukin 6 Antibiotic prescribing C-reactive protein chemistry.chemical_compound Tocilizumab Medicine skin and connective tissue diseases Letter to the Editor biology business.industry Antagonist COVID-19 Blood stream infection Infectious Diseases chemistry Immunology biology.protein CRP business Blood stream |
| Zdroj: | The Journal of Infection |
| Popis: | C-reactive protein (CRP) levels are elevated following bacterial infections but may be attenuated by the IL-6-receptor antagonist tocilizumab. In hospitalised COVID-19 patients, tocilizumab induced a transient ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|